AUSTIN, Texas, Aug. 7 /PRNewswire-FirstCall/ -- Introgen Therapeutics, Inc. , a biopharmaceutical company focused on the discovery, development and commercialization of targeted molecular therapies for the treatment of cancer and other diseases, will hold its quarterly conference call to discuss second quarter results on Wednesday, August 9, 2006, at 4:30 p.m. Eastern Time (3:30 p.m. Central Time).
This call is being webcast by Thomson/CCBN and can be accessed at Introgen’s Web site at www.introgen.com.
The webcast is also being distributed through the Thomson StreetEvents Network. Individual investors can listen to the call at www.earnings.com, Thomson’s individual investor portal, powered by StreetEvents. Institutional investors can access the call via Thomson StreetEvents (www.streetevents.com), a password-protected event management site.
About Introgen Therapeutics, Inc.
Introgen Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted molecular therapies for the treatment of cancer and other diseases. Introgen is developing molecular therapeutics, immunotherapies, vaccines and nano-particle tumor suppressor therapies to treat a wide range of cancers using tumor suppressors, cytokines and genes. Introgen maintains integrated research, development, manufacturing, clinical and regulatory departments and operates multiple manufacturing facilities including a commercial scale cGMP manufacturing facility.
Contact Information: Media Contact Channing Burke, 512 708 9310 ext 322 c.burke@introgen.com
Introgen Therapeutics, Inc.
CONTACT: Media Contact, Channing Burke of Introgen Therapeutics, Inc.,+1-512-708-9310 ext 322, or c.burke@introgen.com
Web site: http://www.introgen.com/
